Literature DB >> 16904192

Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist--a putative role for substance P in CNS inflammation.

Stefan Nessler1, Christine Stadelmann, Alwina Bittner, Kerstin Schlegel, Felix Gronen, Wolfgang Brueck, Bernhard Hemmer, Norbert Sommer.   

Abstract

Substance P (SP) is an excitatory neurotransmitter in the central and peripheral nervous system. Most of its physiological functions are mediated through binding to the neurokinin-1 receptor (NK-1R). Recently, proinflammatory properties of SP have been described. In this study we utilized T cell transfer experimental autoimmune encephalomyelitis (EAE) to investigate the role of SP in CNS autoimmune disease. Treatment with the NK-1R antagonist CP-96,345 dramatically reduced clinical and histological signs of EAE if administered before disease onset. The protective effect of CP96,345 treatment was related to a reduced expression of the adhesion molecules ICAM-1 and VCAM-1 on CNS endothelia. The cellular composition or activation status of splenocytes was not affected by CP-96,345 administration, while the secretion of proinflammatory Th1 cytokines was reduced in treated animals. Th2 cytokines remained largely unaffected by NK-1 receptor antagonist treatment. In summary, our findings suggest that the protective effect of CP96,345 treatment is mediated by stabilization of the blood-brain barrier and suppression of Th1 immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904192     DOI: 10.1016/j.jneuroim.2006.06.026

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  19 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

Authors:  Alejandra N Martinez; Mario T Philipp
Journal:  J Neurol Neuromedicine       Date:  2016

Review 3.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 4.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 5.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 6.  Role of neurotransmitters in immune-mediated inflammatory disorders: a crosstalk between the nervous and immune systems.

Authors:  Mojgan Oshaghi; Masoumeh Kourosh-Arami; Maryam Roozbehkia
Journal:  Neurol Sci       Date:  2022-09-28       Impact factor: 3.830

7.  Elevated serum substance P during simian varicella virus infection in rhesus macaques: implications for chronic inflammation and adverse cerebrovascular events.

Authors:  Andrew N Bubak; Vicki Traina-Dorge; Christina N Como; Brittany Feia; Catherine M Pearce; Laura Doyle-Meyers; Arpita Das; Jayme Looper; Ravi Mahalingam; Maria A Nagel
Journal:  J Neurovirol       Date:  2020-09-22       Impact factor: 2.643

Review 8.  Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Authors:  Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; Omar Khan; Hans-Peter Hartung; Olaf Stüve
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Neuropeptide substance P and the immune response.

Authors:  Alireza Mashaghi; Anna Marmalidou; Mohsen Tehrani; Peter M Grace; Charalabos Pothoulakis; Reza Dana
Journal:  Cell Mol Life Sci       Date:  2016-06-17       Impact factor: 9.261

10.  Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.

Authors:  Peng Jin; Shuixiang Deng; Prativa Sherchan; Yuhui Cui; Lei Huang; Gaigai Li; Lifei Lian; Shucai Xie; Cameron Lenahan; Zachary D Travis; John H Zhang; Ye Gong; Jiping Tang
Journal:  Neurotherapeutics       Date:  2021-07-09       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.